International Technidyne Corporation (ITC), a wholly owned subsidiary of Thoratec Corporation (THOR on NASDAQ), is a worldwide leader in the development, manufacturing, and marketing of point-of-care hemostasis management products for use in hospitals, physician's offices, and the home. ITC is also a leader in the manufacture of single use skin incision devices. ITC's mission is to design, develop, manufacture and market high-quality test systems and services that provide fast and accurate results. ITC is committed to partnering with the healthcare community to reduce healthcare costs and improve patient outcomes.

ITC was founded in 1969 and set the standard for coagulation testing that the market still follows today. ITC is the leader in point-of-care hemostasis testing in cardiac bypass surgery, cardiac catheterization, and dialysis. ITC's innovative line of HEMOCHRON® products provide the broadest menu of tests in the industry at a low cost to the customer. ITC's innovative ProTime® INR monitor was the first coagulation system to receive FDA approval for home use.

ITC's strategy is to build upon its leading market position in hemostasis by leveraging its proprietary point-of-care technology into new medical opportunities. ITC is expanding its marketing and selling efforts outside the USA; developing strategic alliances with other POC companies; and focusing internal product development on next generation products and new assays. In addition, ITC is dedicated to continuous improvement in the quality and reliability of its product lines.